Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230506 | 0.87 | TSHR (0.46) | TSHRTRPV1CHRM2CHRM4CHRM1 | |
| SCHEMBL10786488 | 0.85 | TSHR (0.43) | TSHRTRPV1CHRM2CHRM4CHRM1 | |
| Acetic Acid SCHEMBL27456969 | 0.82 | TSHR (0.31) | TSHRTRPV1ALOX15 | |
| SCHEMBL10782810 | 0.82 | TSHR (0.50) | TSHRTRPV1CHRM2CHRM4CHRM1 | |
| SCHEMBL11140994 | 0.81 | ALDH1A1 (0.44) | TSHRPRKCALMNAALDH1A1 | |
| SCHEMBL542324 | 0.79 | TSHR (0.48) | TSHRTRPV1CHRM2CHRM4CHRM1 | |
| SCHEMBL27858695 | 0.79 | TSHR (0.39) | TSHRTRPV1CHRM2CHRM4CHRM1 | |
| SCHEMBL6895761 | 0.79 | TSHR (0.39) | TSHRTRPV1CHRM2CHRM4CHRM1 | |
| SCHEMBL8004205 | 0.79 | SMPD1 (0.48) | MAPTPRKCAALDH1A1 | |
| SCHEMBL11483358 | 0.77 | SMPD1 (0.52) | MAPTPRKCALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694088-B2 | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer | IMMUNOMEDICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170000896-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | IMMUNOMEDICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9486536-B2 | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer | IMMUNOMEDICS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160166708-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | IMMUNOMEDICS, INC. | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166708-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | P2RX2, ENTPD1, P2RX1 | TSHR 1173/4885TRPV1 1423/4885CHRM2 3248/4885 |
| US-20170000896-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | P2RX2, ENTPD1, P2RX1 | TSHR 1173/4885TRPV1 1423/4885CHRM2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.